Skip to main content
Top
Published in: Pediatric Nephrology 11/2017

01-11-2017 | Original Article

Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients

Authors: Derisha Naicker, Peter W. Reed, Jane Ronaldson, Tonya Kara, William Wong, Chanel Prestidge

Published in: Pediatric Nephrology | Issue 11/2017

Login to get access

Abstract

Background

Bioequivalence between Tacrolimus Prograf® and generic tacrolimus formulations has been demonstrated in adult populations, however clinical experience and safety data regarding generic tacrolimus in pediatric transplant recipients is limited. This study aimed to evaluate conversion from Tacrolimus Prograf® to Sandoz® in pediatric renal transplant recipients nationwide. The primary outcome was a change in mean trough tacrolimus concentration. Additionally, changes in tacrolimus intra-patient coefficient of variation (CoV), allograft function, requirement for dose adjustments, and episodes of biopsy-proven rejection were evaluated.

Methods

Retrospective cohort study in 37 pediatric renal transplant recipients who switched to Tacrolimus Sandoz®. Each patient had three pre-conversion tacrolimus trough and creatinine concentrations within the 4 months prior and three post-conversion concentrations on day 3, 10, and the next subsequent level. Mean pre- and post-conversion tacrolimus trough concentrations and glomerular filtration rate (eGFR) were calculated. Tacrolimus concentration, CoV, and creatinine differences were compared by paired t test.

Results

Thirty-seven patients (41% females, age 3–18 years) were included. Average intra-patient difference in trough tacrolimus concentration was 0.05μg/l (95% CI –0.37 to 0.47). Average intra-patient difference in eGFR was −1.20 ml/min/1.732 (95% CI –3.53 to 1.13). Three patients had acute rejection during 12 months post-conversion compared to none during 12 months pre-conversion.

Conclusions

Pediatric renal transplant recipients can be converted from Tacrolimus Prograf® to Sandoz® with negligible change in trough concentration, dose adjustments, or immediate allograft function. Of concern was the number of acute rejection episodes, however non-adherence contributed to at least one episode and this difference was determined clinically and statistically not significant.
Literature
1.
go back to reference Kidney Disease: Improving Global Outcomes (KDIGO) (2009) Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S157 Kidney Disease: Improving Global Outcomes (KDIGO) (2009) Clinical practice guideline for the care of kidney transplant recipients. Am J Transplant 9(Suppl 3):S1–S157
2.
go back to reference Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, Bunnapradist S, Leichtman A, William Bennett MW, Tejani A, Takemoto SK (2003) Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 3:1211–1215CrossRefPubMed Alloway RR, Isaacs R, Lake K, Hoyer P, First R, Helderman H, Bunnapradist S, Leichtman A, William Bennett MW, Tejani A, Takemoto SK (2003) Report of the American Society of Transplantation conference on immunosuppressive drugs and the use of generic immunosuppressants. Am J Transplant 3:1211–1215CrossRefPubMed
3.
4.
go back to reference Molnar AO, Fergusson D, Tsampalieros AK, Bennett A, Fergusson N, Ramsay T, Knoll GA (2015) Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ 350:h3163CrossRefPubMedPubMedCentral Molnar AO, Fergusson D, Tsampalieros AK, Bennett A, Fergusson N, Ramsay T, Knoll GA (2015) Generic immunosuppression in solid organ transplantation: systematic review and meta-analysis. BMJ 350:h3163CrossRefPubMedPubMedCentral
5.
go back to reference Marfo K, Aitken S, Akalin E (2013) Clinical outcomes after conversion from brand-name tacrolimus (Prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study. PT 38:484–488 Marfo K, Aitken S, Akalin E (2013) Clinical outcomes after conversion from brand-name tacrolimus (Prograf) to a generic formulation in renal transplant recipients: a retrospective cohort study. PT 38:484–488
6.
go back to reference Taube D, Jones G, O'Beirne J, Wennberg L, Connor A, Rasmussen A, Backman L (2014) Generic tacrolimus in solid organ transplantation. Clin Transpl 28:623–632CrossRef Taube D, Jones G, O'Beirne J, Wennberg L, Connor A, Rasmussen A, Backman L (2014) Generic tacrolimus in solid organ transplantation. Clin Transpl 28:623–632CrossRef
7.
go back to reference Mansukhani GP, Conway J (2015) Generic immunosuppression: should we be worried? Pediatr Transplant 19:818–819CrossRefPubMed Mansukhani GP, Conway J (2015) Generic immunosuppression: should we be worried? Pediatr Transplant 19:818–819CrossRefPubMed
8.
go back to reference Abdulnour HA, Araya CE, Dharnidharka VR (2010) Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr Transplant 14:1007–1011CrossRefPubMed Abdulnour HA, Araya CE, Dharnidharka VR (2010) Comparison of generic tacrolimus and Prograf drug levels in a pediatric kidney transplant program: brief communication. Pediatr Transplant 14:1007–1011CrossRefPubMed
9.
go back to reference Davit BM, Nwakama PE, Buehler GI (2009) Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 43:1583–1597CrossRefPubMed Davit BM, Nwakama PE, Buehler GI (2009) Comparing generic and innovator drugs: a review of 12 years of bioequivalence data from the United States Food and Drug Administration. Ann Pharmacother 43:1583–1597CrossRefPubMed
10.
go back to reference Rosenborg S, Nordström A, Almquist T, Wennberg L, Bárány P (2014) Systematic conversion to generic tacrolimus in stable kidney transplant recipients. Clin Kidney J 7:151–155CrossRefPubMedPubMedCentral Rosenborg S, Nordström A, Almquist T, Wennberg L, Bárány P (2014) Systematic conversion to generic tacrolimus in stable kidney transplant recipients. Clin Kidney J 7:151–155CrossRefPubMedPubMedCentral
12.
go back to reference Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Blood RD (2012) A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 13:2825–2831CrossRef Alloway RR, Sadaka B, Trofe-Clark J, Wiland A, Blood RD (2012) A randomized pharmacokinetic study of generic tacrolimus versus reference tacrolimus in kidney transplant recipients. Am J Transplant 13:2825–2831CrossRef
14.
go back to reference Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637CrossRefPubMedPubMedCentral Schwartz GJ, Muñoz A, Schneider MF, Mak RH, Kaskel F, Warady BA, Furth SL (2009) New equations to estimate GFR in children with CKD. J Am Soc Nephrol 20:629–637CrossRefPubMedPubMedCentral
16.
go back to reference McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S (2011) A multicenter experience with generic tacrolimus conversion. Transplantation 92:653–657CrossRefPubMed McDevitt-Potter LM, Sadaka B, Tichy EM, Rogers CC, Gabardi S (2011) A multicenter experience with generic tacrolimus conversion. Transplantation 92:653–657CrossRefPubMed
17.
go back to reference Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R (2011) The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 11:1861–1867CrossRefPubMed Momper JD, Ridenour TA, Schonder KS, Shapiro R, Humar A, Venkataramanan R (2011) The impact of conversion from Prograf to generic tacrolimus in liver and kidney transplant recipients with stable graft function. Am J Transplant 11:1861–1867CrossRefPubMed
18.
go back to reference Duong SQ, Lal AK, Joshi R, Feingold B, Venkataramanan R (2015) Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients. Pediatr Transplant 19:911–917CrossRefPubMed Duong SQ, Lal AK, Joshi R, Feingold B, Venkataramanan R (2015) Transition from brand to generic tacrolimus is associated with a decrease in trough blood concentration in pediatric heart transplant recipients. Pediatr Transplant 19:911–917CrossRefPubMed
Metadata
Title
Nationwide conversion to generic tacrolimus in pediatric kidney transplant recipients
Authors
Derisha Naicker
Peter W. Reed
Jane Ronaldson
Tonya Kara
William Wong
Chanel Prestidge
Publication date
01-11-2017
Publisher
Springer Berlin Heidelberg
Published in
Pediatric Nephrology / Issue 11/2017
Print ISSN: 0931-041X
Electronic ISSN: 1432-198X
DOI
https://doi.org/10.1007/s00467-017-3707-3

Other articles of this Issue 11/2017

Pediatric Nephrology 11/2017 Go to the issue